british journal of pharmacology

[1] Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?

[2] efficacy and safety of sarilumab in combination with csdmards or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase iii randomized, controlled studies

[3] population pharmacodynamic model of neutrophil margination and tolerance to describe effect of sarilumab on absolute neutrophil count in patients with rheumatoid arthritis

[4] efficacy and safety of sarilumab in combination with csdmards or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase iii randomized, controlled studies